Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 11 04:00PM ET
18.95
Dollar change
0.00
Percentage change
0.00
%
CategoryTarget Date / Multi-Asset - Other Asset TypeMulti-Asset - Tactical / Active TagsGlobal Return% 1Y-1.38% Shs Outstand Perf Week-1.03%
SponsorEvoke Advisors ETF Type Tagsequity Return% 3Y-3.35% Total Holdings107 Perf Month-0.79%
Fund Family Bond Type Tagstreasuries Return% 5Y- AUM633.22M Perf Quarter1.55%
Index- Average Maturity Tagscommodity Return% 10Y NAV% Perf Half Y9.22%
Index Weighting Commodity Type Tagsinflation Return% SI NAV/sh Perf Year-4.34%
Active/Passive Quant Type Tags- Flows% 1M-0.45% 52W Range16.71 - 19.98 Perf YTD-0.94%
Dividend TTM0.57 (3.03%) ESG Type Tags- Flows% 3M0.44% 52W High-5.16% Beta0.65
Dividend Ex-DateMar 25, 2024 Dividend Type Sector/Theme Flows% YTD0.21% 52W Low13.41% ATR (14)0.15
Expense0.50% Structure Type Region Flows% 1Y RSI (14)47.39 Volatility0.65% 0.58%
Option/ShortYes / Yes Growth/Value Dev/Emerg Flows% 3Y Rel Volume0.00 Prev Close18.95
Inverse/Leveraged Market Cap Currency Flows% 5Y Avg Volume74.98K Price18.95
SMA20-0.52% SMA500.51% SMA2002.51% Trades Volume0 Change0.00%
RPAR Risk Parity ETF seeks to generate positive returns during periods of economic growth, preserve capital during periods of economic contraction, and preserve real rates of return during periods of heightened inflation. The fund is an actively-managed exchange-traded fund that seeks to achieve its investment objective primarily by investing across a variety of asset classes, including exposure to global equity securities, U.S. Treasury securities, and commodities. It's investment adviser seeks to invest the fund's assets to achieve exposures similar to those of the Advanced Research Risk Parity Index.